Cargando…

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1

The humanised HMFG-1 immunoglobulin has been extensively developed as a clinical immunotherapeutic agent for MUC1 expressing tumours. We have constructed a single-chain Fv (scFv) and Fab fragment from this antibody and shown that both these species retain their specificity for MUC1. The scFv was les...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pericleous, L M, Richards, J, Epenetos, A A, Courtenay-Luck, N, Deonarain, M P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216111/ https://www.ncbi.nlm.nih.gov/pubmed/16265351 http://dx.doi.org/10.1038/sj.bjc.6602847

Ejemplares similares

Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer
por: Royer, B, et al.
Publicado: (2010)

Impact of antibody framework residue V(H)-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme
por: Krauss, J, et al.
Publicado: (2004)

Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen
por: Conaghan, P J, et al.
Publicado: (2008)

MUC-1 expression in pleomorphic adenomas using two human milk fat globule protein membrane antibodies (HMFG-1 and HMFG-2)
por: PONCE-BRAVO, Santa, et al.
Publicado: (2015)

Enhanced photodynamic destruction of a transplantable fibrosarcoma using photochemical internalisation of gelonin
por: Dietze, A, et al.
Publicado: (2005)

Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells
por: Adigbli, D K, et al.
Publicado: (2007)

The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer.
por: Berry, N., et al.
Publicado: (1985)

A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.
por: Dhokia, B., et al.
Publicado: (1986)

Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas
por: Mineo, J-F, et al.
Publicado: (2004)

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
por: Akashi, Y, et al.
Publicado: (2008)

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy
por: Hudson, R, et al.
Publicado: (2005)

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
por: Ruf, P, et al.
Publicado: (2007)

Axillary node status in breast cancer patients prior to surgery by imaging with Tc-99m humanised anti-PEM monoclonal antibody, hHMFG1
por: Al-Yasi, A R, et al.
Publicado: (2002)

Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells
por: Moniaux, N, et al.
Publicado: (2007)

Kinetics, quantitative analysis and radioimmunolocalization using indium-111-HMFG1 monoclonal antibody in patients with breast cancer.
por: Kalofonos, H. P., et al.
Publicado: (1989)

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models
por: El-Emir, E, et al.
Publicado: (2007)

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
por: Panousis, C, et al.
Publicado: (2005)

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine
por: Overman, M J, et al.
Publicado: (2010)

Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy
por: Faisal, Amir, et al.
Publicado: (2017)

Cell migration in paediatric glioma; characterisation and potential therapeutic targeting
por: Cockle, J V, et al.
Publicado: (2015)

Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI
por: Gambarota, G, et al.
Publicado: (2008)

Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines
por: Salawu, Abdulazeez, et al.
Publicado: (2016)

Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery
por: Wang, Y, et al.
Publicado: (2005)

FAT1: a potential target for monoclonal antibody therapy in colon cancer
por: Pileri, Piero, et al.
Publicado: (2016)

An anti-MUC1-antibody–interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells
por: Heuser, C, et al.
Publicado: (2003)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

Characterisation of the anti-apoptotic function of survivin-ΔEx3 during TNFα−mediated cell death
por: Malcles, M-H, et al.
Publicado: (2007)

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
por: Pukac, L, et al.
Publicado: (2005)

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
por: Smith, L M, et al.
Publicado: (2008)

Characterisation of a humanised bispecific monoclonal antibody for cancer therapy.
por: Bruynck, A., et al.
Publicado: (1993)

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
por: Montagut, C, et al.
Publicado: (2010)

Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation
por: de Plater, L, et al.
Publicado: (2010)

Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer
por: Williamson, S C, et al.
Publicado: (2013)

Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis
por: Hardee, M E, et al.
Publicado: (2005)

Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair
por: Ratner, Elena S, et al.
Publicado: (2016)

Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
por: Patterson, M J, et al.
Publicado: (2014)

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets
por: Wattenberg, M M, et al.
Publicado: (2014)

Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases
por: Kim, S H, et al.
Publicado: (2008)

Human recombinant anti-thyroperoxidase autoantibodies: in vitro cytotoxic activity on papillary thyroid cancer expressing TPO
por: Rebuffat, S A, et al.
Publicado: (2010)

Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens.
por: Kosmas, C., et al.
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_dfo93s50ufr3nuj405ov6g2ca7